Vol. 22/No. 22 | OncologyLive

New Players Join Quest for a Therapeutic Foothold Against TGFβ

January 03, 2022


Bintrafusp Alfa, a novel fusion protein designed to target the transforming growth factor beta pathway, racked up 3 clinical trial disappointments in less than a year, leaving the future of its development in question.

COVID-19 Pandemic Highlights Underrecognized Vulnerability of Patients With CLL

December 24, 2021

Partner Perspective

At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.

Therapeutic Frontiers Expand for Patients With Relapsed/Refractory Multiple Myeloma

December 06, 2021

Various immune strategies have been developed in multiple myeloma, including immune-enhancing drugs such as immunomodulatory drugs, checkpoint inhibitors, monoclonal antibodies, and, more recently, chimeric antigen receptor T-cell therapy and bispecific antibodies for T-cell redirection.

Oncology Drug Regulation Faces an Uncertain Future

December 01, 2021

From the Editor

Maurie Markman, MD, discusses how agency leaders should be encouraged to improve regulatory science, include a patient’s perspective in approval decisions, reduce unnecessary bureaucracy and costs associated with the conduct of trials, and accelerate the overall review process for drug approval.